Zantac Recall

Zantac Recall

Zantac Recalled Due to Potential Cancer Risk

On April 1, 2019, the Food and Drug Administration (FDA) recalled all prescription and over-the-counter Zantac (Ranitidine) drugs from the market. This was the latest step in a long running investigation related to contaminated Zantac. The FDA determined that the contaminate known as N-Nitrosodimethylamine (NDMA) increased over time and when stored at room temperatures may expose consumers to unacceptable levels of NDMA.


NDMA is a known human carcinogen – meaning is could cause cancer. Lawsuits claim that Zantac cause the following types of cancer:

  • Bladder Cancer
  • Colorectal Cancer
  • Esophageal Cancer
  • Intestinal Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Testicular Cancer
  • Uterine or Ovarian Cancer

Yaeger Law is investigating cases in which patients took Zantac or generic forms of Rantidine and then developed certain cancers. If you or a loved one experienced injuries related to Zantac, you may be entitled to compensation. Contact Yaeger Law to discuss the details of your potential Zantac Lawsuit.

TIMELINE OF RECALLS:

11/19/2019: Precision Dose recalls ranitidine oral solution, USP 150 mg/10 ml due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.

11/15/2019: Golden State Medical Supply (GSMS, Inc.) recalls ranitidine HCl 150mg and 300mg capsules due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.

11/8/2019: Amneal Pharmaceuticals recalls ranitidine tablets, 150 mg and 300 mg, and ranitidine syrup (ranitidine oral solution, USP), 15 mg/ml due to due to potential n-nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

11/8/2019: American Health Packaging recalls ranitidine liquid unit dose cups due to NDMA impurity.

11/6/2019: Aurobindo & DG Health recalls ranitidine due to NDMA impurity.

10/25/2019: Novitium Pharma recalls ranitidine hydrochloride capsules 150 mg and 300 mg because it may contain n-nitrosodimethylamine (NDMA).

10/25/2019: Lannett Company, Inc. recalls ranitidine syrup (ranitidine oral solution, USP), 15mg/ml due to above levels of NDMA.

10/23/2019: Dr. Reddy’s, Kroger, Walgreens, and others recall ranitidine tablets & capsules for containing N-Nitrosodimethylamine (NDMA).

10/23/2019: Perrigo Company plc recalls Ranitidine (all pack sizes) for the presence of N-Nitrosodimethylamine (NDMA).

10/22/2019: Sanofi recalls all Zantac OTC products in the U.S. for possibly containing N-Nitrosodimethylamine (NDMA).

9/25/2019: Apotex Corp. recalls 75mg and 150mg ranitidine tablets for containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA)

9/23/2019: Sandoz Inc. recalled ranitidine hydrochloride capsules due to an elevated amount of an unexpected impurity, N-nitrosodimethylamine (NDMA)